<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/25/brokerages-expect-nucana-plc-nasdaqncna-to-post-0-22-eps.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-25T13:25:03+00:00"/>
    <meta property="og:title" content="Brokerages Expect NuCana PLC (NASDAQ:NCNA) to Post -$0.22 EPS"/>
    <meta property="og:description" content="Wall Street brokerages expect NuCana PLC (NASDAQ:NCNA) to post ($0.22) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for NuCana’s earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.18). NuCana posted earnings per share of ($0.14) in the same quarter last year, which […]"/>
  </head>
  <body>
    <article>
      <h1>Brokerages Expect NuCana PLC (NASDAQ:NCNA) to Post -$0.22 EPS</h1>
      <address><time datetime="2019-11-25T13:25:03+00:00">25 Nov 2019, 13:25</time> by <a rel="author" href="https://www.thecerbatgem.com/author/amy" target="_blank">Amy Steele</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/nucana-plc-logo.png"/>
      </figure>
      <p>Wall Street brokerages expect NuCana PLC (NASDAQ:NCNA) to post ($0.22) earnings per share (EPS) for the current quarter, <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> reports. Zero analysts have issued estimates for NuCana’s earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.18). NuCana posted earnings per share of ($0.14) in the same quarter last year, which would indicate a negative year-over-year growth rate of 57.1%. The company is scheduled to announce its next earnings results on Thursday, March 5th.</p>
      <p>Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover NuCana.</p>
      <p>NuCana (NASDAQ:NCNA) last issued its earnings results on Wednesday, November 13th. The company reported ($12.00) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($22.80) by $10.80.</p>
      <p>Several research analysts recently issued reports on the stock. BidaskClub raised shares of NuCana from a “hold” rating to a “buy” rating in a report on Tuesday, September 10th. Cowen restated a “buy” rating on shares of NuCana in a research report on Friday, October 25th. HC Wainwright restated a “buy” rating and set a $17.00 price target (down previously from $20.00) on shares of NuCana in a research report on Friday, November 15th. Citigroup set a $25.00 price target on shares of NuCana and gave the company a “buy” rating in a research report on Wednesday, August 21st. Finally, William Blair restated a “buy” rating on shares of NuCana in a research report on Thursday, September 5th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. NuCana presently has an average rating of “Buy” and an average target price of $16.13.</p>
      <p>Several hedge funds and other institutional investors have recently made changes to their positions in the company. Susquehanna International Group LLP acquired a new stake in shares of NuCana in the second quarter valued at about $139,000. Tower Research Capital LLC TRC purchased a new position in NuCana in the second quarter valued at approximately $32,000. BlackRock Inc. raised its holdings in NuCana by 134,310.2% in the second quarter. BlackRock Inc. now owns 608,878 shares of the company’s stock valued at $6,320,000 after buying an additional 608,425 shares during the period. Asymmetry Capital Management L.P. raised its holdings in NuCana by 257.8% in the second quarter. Asymmetry Capital Management L.P. now owns 162,414 shares of the company’s stock valued at $1,686,000 after buying an additional 117,021 shares during the period. Finally, Aperio Group LLC purchased a new position in NuCana in the second quarter valued at approximately $39,000. Institutional investors and hedge funds own 27.59% of the company’s stock.</p>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/NASDAQ/NCNA/earnings/">NuCana stock</a> traded up $0.74 during trading on Monday, hitting $7.84. 1,704 shares of the company’s stock were exchanged, compared to its average volume of 62,588. The business has a 50-day simple moving average of $6.64 and a 200-day simple moving average of $9.45. NuCana has a 52-week low of $4.01 and a 52-week high of $19.90. The stock has a market capitalization of $215.82 million, a price-to-earnings ratio of -13.75 and a beta of 3.11.</p>
      <p>
        <b>About NuCana</b>
      </p>
      <p>NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.</p>
      <p>See Also: <a href="https://www.marketbeat.com/financial-terms/leveraged-buyout-explained/">Leveraged Buyout (LBO)</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=NCNA">Get a free copy of the Zacks research report on NuCana (NCNA)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=NCNA"/>
      </figure>
    </article>
  </body>
</html>